Drugs / Cenergermin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT07073729 Comparator | Aug 2025 → Aug 2026 overdue | neurotrophic keratopathy | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cenergermin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07073729 ↗ |
| Modality | Protein / enzyme biologic | “Topical recombinant human nerve growth factor (rhNGF)” NCT07073729 ↗ |
| Route | Topical | “Administered as eye drops” NCT07073729 ↗ |